Research Topics
Species | Smriti IyengarSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in ratsSmriti Iyengar
Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Pharmacol Exp Ther 311:576-84. 2004..These data suggest that inhibition of both 5-HT and NE uptake may account for attenuation of persistent pain mechanisms. Thus, duloxetine may have utility in treatment of human persistent and neuropathic pain states...- Efficacy and safety of duloxetine in patients with chronic low back painVladimir Skljarevski
Lilly Research Laboratories, Indianapolis, IN, USA
Spine (Phila Pa 1976) 35:E578-85. 2010..This was a randomized, double-blind, placebo-controlled clinical trial... - Duloxetine vs. placebo in patients with painful diabetic neuropathyDavid J Goldstein
PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
Pain 116:109-18. 2005..Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain... - Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trialAmy S Chappell
Lilly Research Laboratories, Indianapolis, IN, USA
Pain 146:253-60. 2009..Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo)... - An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic painJoachim F Wernicke
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Pain Med 8:503-13. 2007..To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare duloxetine with routine care in the management of patients with diabetic peripheral neuropathic pain (DPNP)... - Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studiesDaniel K Kajdasz
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
Clin Ther 29:2536-46. 2007.... - The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depressionFrank P Bymaster
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
Curr Pharm Des 11:1475-93. 2005..More importantly, duloxetine appears to have better response rates and remission from depressive symptoms, perhaps due to its ability to treat a wider range of symptoms... - Effects of duloxetine on painful physical symptoms associated with depressionDavid J Goldstein
Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
Psychosomatics 45:17-28. 2004..Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression... - The role of uninjured nerve in spinal nerve ligated rats points to an improved animal model of neuropathic painDoo H Lee
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Eur J Pain 7:473-9. 2003..The addition of a chromic gut loop around the intact L4 spinal nerve can augment the development of mechanical allodynia following SNL of L5. We propose this latter as a useful and practical animal model of neuropathic pain... - Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of painEsteban Dominguez
Centro de Investigación Lilly, S A Avda De la Industria 30, 28108 Alcobendas, Madrid, Spain
J Med Chem 48:4200-3. 2005..Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia... - A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic painJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
Pain Med 6:346-56. 2005..Assess efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, on the reduction of pain severity, in patients with diabetic peripheral neuropathic pain (DPNP)... - Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic painJoel Raskin
Lilly Research Laboratories, Toronto, Canada
J Palliat Med 9:29-40. 2006.... - Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in ratsRosa Maria A Simmons
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Mail Drop 0510, Indianapolis, IN 46285, USA
Pharmacol Biochem Behav 73:419-27. 2002..These results support the involvement of Group II mGlu2,3 receptors in persistent pain mechanisms and suggest the potential utility of selective Group II mGlu agonists for the treatment of persistent pain... - Depression and painMichael J Robinson
Lilly USA, LLC, Indianapolis, IN 46285, USA
Front Biosci 14:5031-51. 2009..To break this cycle, it is important to treat all symptoms of a patient. Therapeutic approaches that address symptoms of both depression and pain include psychotherapy, exercise, and pharmacotherapy... - Antiallodynic and antihyperalgesic effects of selective competitive GLUK5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in ratsCarrie K Jones
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Pharmacol Exp Ther 319:396-404. 2006..The present studies provide further evidence that selective Glu(K5) kainate receptor subtype antagonists can reverse allodynia and hyperalgesia, particularly in persistent pain states... - Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorderJohannes Tauscher
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
Eur Neuropsychopharmacol 20:80-7. 2010..Thus, further evaluation of LY686017 for the treatment of SAD does not seem warranted... - Corticotropin-releasing factor mRNA and substance P receptor binding in the paraventricular hypothalamic nucleus, central nucleus of the amygdala, and locus coeruleus of Sprague-Dawley rats following restraint-induced stressBang H Hwang
Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
J Mol Neurosci 25:239-50. 2005..In concert with the literature indicating SP antagonist's antidepressive effects, up-regulated SP receptors in the CeA might contribute to the development of stress-related depression... - AMPA receptor potentiation can prevent ethanol-induced intoxicationNicholas Jones
Neuroimaging Research Group, Institute of Psychiatry, Kings College London, London, UK
Neuropsychopharmacology 33:1713-23. 2008.... - A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorderLesley M Arnold
Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA
Pain 119:5-15. 2005..In conclusion, both duloxetine 60 mg QD and duloxetine 60 mg BID were effective and safe in the treatment of fibromyalgia in female patients with or without major depressive disorder... - Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trialsLesley M Arnold
Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA
J Womens Health (Larchmt) 16:1145-56. 2007.... - A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorderLesley M Arnold
University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, USA
Arthritis Rheum 50:2974-84. 2004..To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder...